Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 13;18(1):20230666. doi: 10.1515/med-2023-0666

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 the author(s), published by De Gruyter

This work is licensed under the Creative Commons Attribution 4.0 International License.

PMC Copyright notice

LANCL1-AS1 upregulation restrains cell migration, invasiveness, and angiogenesis of NSCLC. (a) RT-qPCR for evaluating the transfection efficiency of pcDNA3.1/LANCL1-AS1 in A549 and H460 cells. (b) The survival rate of NSCLC cells with or without LANCL1-AS1 overexpression under gefitinib treatment. (c) CCK-8 assay for evaluating the viability of LANCL1-AS1-overexpressed A549 and H460 cells. (d and e) Transwell assays for evaluating cell migratory and invasive capabilities after LANCL1-AS1 overexpression. (f) Tube formation assay for assessing angiogenic ability of HUVECs with LANCL1-AS1 upregulation. (g) Western blotting for evaluating levels of angiogenesis-related proteins. ^** p < 0.01, ^*** p < 0.001.